Single dose of Profectus' Ebola vaccine works in monkeys
This article was originally published in Scrip
Executive Summary
A single dose of Profectus BioSciences' experimental Ebola vaccine, which uses the firm's VesiculoVax vector platform, provided rapid and complete protection from sickness and death in macaques when challenged with a lethal dose of the Makona form of the Zaire virus – the strain responsible for the ongoing epidemic in West Africa, which has infected more than 25,500 people, killing over 10,500.